Global Autoinjectors Market (4th Edition) by Type of Autoinjector (Disposable and Reusable), Route of Administration (Subcutaneous and Intramuscular), Type of Molecule (Monoclonal Antibody, Peptide, Protein, and Small Molecule), Therapeutic Indication (Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis, Migraine, Diabetes, and Others) and Geography (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2022

  • Pages
    610

  • View Count
    25772

Example Insights

Global-Autoinjectors-Market-Context-thumb Global-Autoinjectors-Market-Autoinjectors-thumb Global-Autoinjectors-Market-Development-thumb Global-Autoinjectors-Market-Peer-Group-thumb Global-Autoinjectors-Market-Patent-Analysis-thumb
Global-Autoinjectors-Market-Opinion-Leaders-thumb Global-Autoinjectors-Market-Collaborations-thumb Global-Autoinjectors-Market-Autoinjector-Developers-thumb Global-Autoinjectors-Market-Manufacturers-thumb Global-Autoinjectors-Market-Case-Study-thumb
Global-Autoinjectors-Market-administration-thumb Global-Autoinjectors-Market-Autoinjectors-Market-thumb Global-Autoinjectors-Market-Type-of-Molecule-thumb    

Overview

According to the National Health Interview Survey (NHIS), nearly 52% of the adult population in the US is diagnosed with at least one chronic condition, such as asthma, diabetes, and hypertension. The annual cost burden associated with chronic disorders in the US is around USD 3.7 trillion; this accounts for nearly 20% of the country’s GDP share. A major share of expenses incurred by patients living with a chronic disorder is driven by the frequent need to medicate, which may require repeated visits to hospitals / out-patient clinics. In addition, patient compliance and adherence to the treatment regimen prove to be a challenge. In order to mitigate this challenge, a wide variety of self-administering injectable drugs have been developed, which impart greater independence and psychological benefits to the patients, as compared to drug administration by healthcare professionals. Amongst the various self-injection devices, autoinjectors have steadily gained prominence, especially for the treatment of emergency and chronic conditions, such as anaphylactic shock and rheumatoid arthritis. The additional features of autoinjectors, such as integrated needle safety, Bluetooth connectivity, and monitoring injection dose history, enable them to resolve several injection-related compliance issues faced by the patients.

Given the inherent benefits of autoinjectors, a number of players have launched their proprietary products in combination with autoinjectors for use across a wide array of disease indications. One of the most widely recognized autoinjector in the market is EpiPen® (Mylan), which is a prefilled epinephrine autoinjector. The generic version of EpiPen received the FDA approval in 2018. Notable examples of other autoinjector-based combination products include Fasenra® Pen (AstraZeneca), Gvoke® Hypopen (Xeris Pharmaceuticals), NUCALA Autoinjector (GlaxoSmithKline), and Vyleesi™ Autoinjector (AMAG Pharmaceuticals® / Palatin Technologies). Apart from being a patient-friendly alternative to conventional drug delivery methods, autoinjectors also serve as potential life cycle management tools; several pharmaceutical players have reformulated their proprietary drugs as autoinjector combination products to expand market exclusivity period. For instance, Amgen reformulated lyophilized Enbrel® for delivery via the SureClick® autoinjector to extend the patent protection of the drug by almost 11 years. Further, it is worth mentioning that several autoinjector developers have made significant efforts in developing novel autoinjector technologies, paving the way for new generation of autoinjector devices. The field is presently witnessing several innovations, such as LED / LCD-based visualization, Bluetooth connectivity, dosage recording, safety lock, visual / audible drug delivery confirmation notifications, and automatic drug reconstitution. In this context, it is worth highlighting that nearly 5,000 patents have been filed / granted, since 2015, for autoinjectors and affiliated products / technologies. We believe that such efforts are likely to drive growth in this market over the coming years.

Scope of the Report

The “Global Autoinjectors Market (4th Edition) by Type of Autoinjector (Disposable and Reusable), Route of Administration (Subcutaneous and Intramuscular), Type of Molecule (Monoclonal Antibody, Peptide, Protein, and Small Molecule), Therapeutic Indication (Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis, Migraine, Diabetes, and Others) and Geography (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of autoinjectors till 2035. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • An overview of the current market landscape of autoinjectors that are either marketed / being developed by various stakeholders, providing information on the usability (disposable and reusable), type of primary drug container (cartridge, syringe and vial), volume of container, type of dose (fixed and variable), route of administration (intradermal, intracavernosal, intramuscular and subcutaneous), actuation mechanism (automatic and manual) and feedback mechanism integrated in the device. It also provides details on the developers, highlighting their year of establishment, company size (small, mid-sized, large and very large), and location of headquarters.
  • A competitiveness analysis of various disposable and reusable autoinjectors, taking into consideration supplier power of their developers (based on year of establishment and company size) and key product specifications, such as route of administration, primary drug container used, injector actuation mechanism, type of dose and user friendliness of the product.
  • A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of product portfolio), highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects, such as strength and diversity of product portfolio, route of administration, actuation mechanism, geographical presence / reach and supplier power of each company.
  • An in-depth analysis of the patents that have been filed / granted for autoinjectors, highlighting trends across key parameters, such as type of patent, publication year, issuing authority, CPC classification, emerging focus areas and leading industry players (on the basis of number of patents). It also includes a detailed patent benchmarking and an insightful valuation analysis.
  • A review of autoinjectors being developed in combination with drugs, featuring details on initial year of approval (for marketed products), phase of development, usability of the device, route of administration (intracavernous, intramuscular and subcutaneous), type of drug molecule (antibody, peptide, protein and small molecule), dose strength, therapeutic area and other approved dosage forms (for marketed products). In addition, the chapter provides details on the developers, including year of establishment, company size and location of headquarters.
  • Detailed case studies on the most commonly targeted indications, covering history of development and detailed description of the approved autoinjector products, along with their respective mechanisms of action and historical sales records. The study also includes a list of the drugs that are currently being delivered via autoinjectors. 
  • A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with autoinjectors in the near future, shortlisted on the basis of an in-depth analysis that takes into consideration various relevant parameters, such as route of administration, type of drug molecule, target indications, other available dosage forms (for approved drugs) and historical annual sales information (for approved drugs).
  • Elaborate profiles of autoinjector manufacturers that have more than three devices in their respective product portfolios; each profile features an overview of the company, its financial information (if available), information on its product portfolio, autoinjector device specifications, collaborations, recent developments and an informed future outlook. Additionally, the report includes brief profiles of emerging players that have been established in the past decade.
  • A list of key opinion leaders (KOLs) within this domain who were short-listed based on their contributions (such as involvement in clinical trials and research publications); it features a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. 
  • An analysis of the recent collaborations (since 2016) focused on the development of autoinjectors. It includes partnerships inked by various stakeholders in this domain, covering licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, mergers and acquisitions, and other relevant agreements. 
  • A SWOT analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market.
  • A case study on the role of CMOs offering services for drug delivery devices; it features a list of service providers, highlighting the various types of services offered for different types of drug-delivery devices.  
  • An overview of the current market landscape of companies engaged in manufacturing prefilled syringes, providing information on year of establishment, company size, geographical location of the headquarters and manufacturing facilities, type of material used (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and syringe volume. 

One of the key objectives of the report was to estimate the existing market size and assess potential future growth opportunities for autoinjector devices. Based on parameters, such as number of commercialized combination products, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2021-2035. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] usability (disposable and reusable), [B] route of administration (subcutaneous and intramuscular), [C] type of molecule (monoclonal antibody, peptide, protein and small molecule) [D] therapeutic indication (anaphylaxis, multiple sclerosis, rheumatoid arthritis, migraine, diabetes and other indications), and [E] key geographies (North America, Europe, Asia-Pacific and rest of the World). 

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals: 

  • David Daily (CEO and Co-founder, DALI Medical Devices) 
  • Barbara Lead (Chief Executive Officer, Oval Medical Technologies)
  • William G. Fortina (Business Development Director-Drug Delivery Systems, Duoject Medical Systems)
  • Douglas Marenzi (Managing Director, PHC Injection Technologies) 
  • Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical)
  • Jesse Fourt (Design Director, IDEO)
  • Dennis Lee (Senior Program Officer in CMC, Bill & Melinda Gates Foundation)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading autoinjector device developers?
  • For which disease indications are autoinjector-based combination products available?
  • Which partnership models are commonly adopted by stakeholders developing autoinjectors?
  • Which drug candidates are likely to be considered for administration via autoinjectors?
  • How has the intellectual property landscape of autoinjectors evolved over the years? 
  • Who are the Key Opinion Leaders across different regions of the world?
  • Who are the leading contract manufacturing organizations providing services for autoinjector devices? 
  • What is the share of autoinjector devices, in terms of revenue generation potential, across different disease markets?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the autoinjectors market in the short-mid term and long term.

Chapter 3 provides a general overview of various devices that enable self-administration of drugs, specifically focusing on autoinjectors. The chapter features a discussion on the historical evolution of autoinjectors, along with details related to their individual components, device categories and associated manufacturing / packaging processes. In addition, it elaborates on the benefits of autoinjectors that have led to their growing adoption over the last several years. The chapter also highlights the existing concerns related to needlestick injuries and the various preventive laws that have been passed worldwide, for addressing the pressing need for introducing advanced safety features in such devices.

Chapter 4 is an overview of the various types of primary drug containers that are utilized in autoinjectors. It features information on current trends related to the use of prefilled syringes and cartridges. In addition, it lists the diverse types of primary drug containers that are available in the market, along with details on companies that are involved in the production of such containers.

Chapter 5 provides information on close to 100 autoinjectors that have already been developed or are under development, and a detailed analysis of these devices based on various relevant parameters, such as primary drug container used (cartridge, prefilled syringe and vial), volume, device usability (disposable and reusable), route of administration (intramuscular, intradermal and subcutaneous) and other technical parameters. In addition, the chapter provides information on manufacturers, along with information on year of establishment, location of headquarters and strength of employee base.

Chapter 6 presents an insightful competitiveness analysis of disposable and reusable autoinjectors (separately) based on the supplier power of the developers and key product specifications, such as route of administration, primary drug container used, mechanism of operation, dosage type and user friendliness. 

Chapter 7 provides an elaborate brand positioning analysis of the leading device developers / manufacturers, highlighting the current perceptions regarding their proprietary brands across different device types. The analysis takes into consideration several aspects, such as strength and diversity of product portfolio, routes of administration, actuation mechanism, geographical presence / reach and supplier power of each player.

Chapter 8 provides an in-depth patent analysis, presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we looked at the patents that have been published by various players since 2015. The analysis highlights the key information associated with these patents, including patent type, publication year, geographical location, CPC classification, emerging areas, leading industry players, patent benchmarking and valuation analysis.

Chapter 9 provides details on the various pipeline and approved products that are being tested or available in autoinjectors. It features a detailed analysis of these drugs, based on the various parameters, such as the target disease indication(s), phase of development, type of drug molecule, route of administration(s), approval year (in case of marketed products), dosage (in case of marketed products) and other approved dosage forms (in case of marketed products). In addition, the chapter provides information on drug developers, year of their establishment, location of headquarters and strength of employee base.  

Chapter 10 provides detailed case studies on the most commonly targeted indications covering history of development and detailed description of the approved autoinjector products, along with mechanism of action and historical sales of the drugs.

Chapter 11 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via autoinjectors in the future. It is worth highlighting that this list has been compiled based on various parameters, such as route of administration, target therapeutic indication(s), other available dosage forms (in case of marketed drugs), type of drug molecule and drug sales of the approved product candidates. For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular). Additionally, we reviewed over 1,500 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via an autoinjector in the future was estimated using the weighted average method. 

Chapter 12 includes detailed profiles of key autoinjector manufacturers. Each profile features an overview of the company, its financial information (if available), information on its product portfolio, autoinjector device specifications, collaborations, recent developments and an informed future outlook.

Chapter 13 includes brief profiles of some of the emerging players in the autoinjectors industry. Each profile features an overview of the company, technology, information on its product portfolio, autoinjector device specifications and recent developments.

Chapter 14 provides an analysis of KOLs in the field of drug-delivery devices, including autoinjectors. It features a comprehensive list of principal investigators / study directors of different clinical trials and patent assignees, along with the information related to the affiliated organizations. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in this domain. It highlights the notable KOLs who have relatively more experience in this domain. The chapter also provides details on different parameters of the KOLs (wherever available), including number of publications, number of citations, number of clinical trials / patents, number of affiliations and extent of professional network.

Chapter 15 features an elaborate discussion and analysis of the various partnerships and collaborations that have been inked between various stakeholder in the industry, since 2016. Further, the partnership activity in this domain has been analyzed on the basis of year of agreement / partnership, the type of partnership model, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, mergers and acquisitions, and others, companies involved, and regional distribution of the collaborations.

Chapter 16 presents a detailed analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market, under a comprehensive SWOT framework.

Chapter 17 is a case study focused on the role of medical device CMOs in the manufacturing and assembly of drug-delivery devices, including autoinjectors. It provides a list of service providers with details on their scale of operation and types of services provided for production of devices.

Chapter 18 provides an overview of around 80 prefilled syringes that are available in the market and provides details on the companies that manufacture such products. It features analyses of the prefilled syringes, based on various parameters, such as type of material (glass and plastic), number of barrel chambers (dual chamber and single chamber), type of needle system (fixed needle system and luer system) and syringe volume. In addition, the chapter provides information on manufacturers, along with information on year of establishment, location of headquarters and manufacturing facilities, and strength of employee base. The chapter also includes a discussion on the technological advances of prefilled syringes that have taken place in the recent past.

Chapter 19 presents an insightful market forecast analysis, highlighting the future potential of the autoinjectors market till the year 2035. We have segregated the opportunity of the market on the basis of [A] usability (disposable and reusable), [B] route of administration (subcutaneous and intramuscular), [C] type of molecule (monoclonal antibody, peptide, protein and small molecule) [D] therapeutic indication (anaphylaxis, multiple sclerosis, rheumatoid arthritis, migraine, diabetes and other indications), and [E] key geographies (North America, Europe, Asia-Pacific and rest of the World). The likely size of the market has been estimated both in terms of value (USD billion) and volume (number of devices).

Chapter 20 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with David Daily (CEO and Co-founder, DALI Medical Devices), Barbara Lead (Chief Executive Officer, Oval Medical Technologies), William G. Fortina (Business Development Director - Drug Delivery Systems, Duoject Medical Systems), Douglas Marenzi (Managing Director, PHC Injection Technologies), Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical), Jesse Fourt (Design Director, IDEO) and Dennis Lee (Senior Program Officer in CMC, Bill & Melinda Gates Foundation)

Chapter 21 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 22 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 23 is an appendix, which provides a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Drug Delivery Systems
3.3. Drawbacks of Conventional Parenteral Delivery Systems
3.4. Needlestick Injuries
3.4.1. Incidence and Cost Burden
3.4.2. Government Legislation for the Prevention of Needlestick Injuries

3.5. Emerging Trend of Self-Administration
3.5.1. Rising Burden of Chronic Diseases
3.5.2. Healthcare Cost Savings
3.5.3. Need for Immediate Treatment in Emergency Situations
3.5.4. Growth of Injectable Biologics Market
3.5.5. Addressing Key User Safety Requirements

3.6. Types of Self-administration Devices
3.6.1. Prefilled Syringes
3.6.2. Pen-Injectors
3.6.3. Needle-Free Injectors
3.6.4. Autoinjectors
3.6.5. Large Volume Wearable Injectors

3.7. Overview of Autoinjectors
3.7.1. Components of Autoinjectors
3.7.2. Classification of Autoinjectors
3.7.2.1. On the Basis of Mechanism of Action
3.7.2.2. On the Basis of Usability
3.7.2.3. On the Basis of Type of Dose
3.7.3. Manufacturing / Packaging of Autoinjectors
3.7.4. Benefits of Autoinjectors

3.8. Regulatory Considerations
3.8.1. Medical Devices
3.8.2. Drug Device Combination Products

3.9. Future Perspectives

4. PRIMARY DRUG CONTAINERS
4.1. Chapter Overview
4.2. Types of Packaging
4.3. Introduction to Primary Drug Containers
4.3.1. Role of Primary Drug Containers
4.3.2. Types of Primary Drug Containers
4.3.2.1. Cartridges
4.3.2.1.1. Components of Cartridges
4.3.2.1.2. Types of Cartridges
4.3.2.1.2.1. Single Chamber Cartridge
4.3.2.1.2.2. Dual Chamber Cartridge

4.3.2.1.3. Cartridges Available in the Market

4.3.2.2. Syringes
4.3.2.2.1. Components
4.3.2.2.2. Types of Syringes
4.3.2.2.2.1. Based on Number of Chambers
4.3.2.2.2.2. Based on Type of Needle

4.3.2.2.3. Prefilled Syringe Systems Available in the Market
4.3.2.2.3.1. Glass Prefilled Syringes
4.3.2.2.3.2. Plastic Prefilled Syringes

4.3.2.3. Vials
4.3.2.3.1. Components
4.3.2.3.2. Vials Available in the Market

4.4. Comparison of Fabrication Materials

5. AUTOINJECTORS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Autoinjectors: Overall Market Landscape
5.2.1. Analysis by Usability
5.2.2. Analysis by Type of Primary Container
5.2.3. Analysis by Volume of Container
5.2.4. Analysis by Dosage Type
5.2.5. Analysis by Route of Administration
5.2.6. Analysis by Actuation Mechanism
5.2.7. Analysis by Type of Feedback Mechanism

5.3. Autoinjectors: Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Geographical Location of Headquarters

6. PRODUCT COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Parameters
6.4. Product Competitiveness Analysis: Disposable Autoinjectors
6.5. Product Competitiveness Analysis: Reusable Autoinjectors

7. BRAND POSITIONING ANALYSIS OF KEY INDUSTRY PLAYERS
7.1 Chapter Overview
7.2. Scope and Methodology
7.3. Brand Positioning Matrix: Antares Pharma
7.4. Brand Positioning Matrix: Becton Dickinson
7.5. Brand Positioning Matrix: Bespak
7.6. Brand Positioning Matrix: DALI Medical Device
7.7. Brand Positioning Matrix: Elcam Medical
7.8. Brand Positioning Matrix: Jiangsu Delfu medical device
7.9. Brand Positioning Matrix: Kaleo
7.10. Brand Positioning Matrix: Oval Medical Technologies
7.11. Brand Positioning Matrix: Owen Mumford
7.12. Brand Positioning Matrix: Pharma Consult
7.13. Brand Positioning Matrix: SHL Medical
7.14. Brand Positioning Matrix: Union Medico
7.15. Brand Positioning Matrix: Ypsomed

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Autoinjectors: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Geography
8.3.3. Analysis by CPC Symbols
8.3.4. Emerging Focus Areas
8.3.5. Analysis by Type of Organization
8.3.6. Leading Players: Analysis by Number of Patents
8.4. Autoinjectors: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.5. Autoinjectors: Patent Valuation Analysis

9. THERAPEUTIC PRODUCTS AVAILABLE IN AUTOINJECTORS
9.1. Chapter Overview
9.2. Autoinjector Combination Products: List of Approved Drugs
9.2.1. Analysis by Initial Year of Approval
9.2.2. Analysis by Usability
9.2.3. Analysis by Route of Administration
9.2.4. Analysis by Primary Drug Container
9.2.5. Analysis by Type of Molecule
9.2.6. Analysis by Dose Strength
9.2.7. Analysis by Therapeutic Indication
9.2.8. Analysis by Other Packaging Formats of Marketed Drugs

9.3. Autoinjector Combination Products: List of Pipeline Drugs
9.3.1. Analysis by Phase of Development
9.3.2. Analysis by Route of Administration
9.3.3. Analysis by Type of Molecule
9.3.4. Analysis by Therapeutic Indication
9.3.5. Grid Analysis: Distribution by Therapeutic Indication, Phase of Development and Route of Administration

9.4. Autoinjector Combination Products: List of Developers
9.4.1. Analysis by Year of Establishment
9.4.2. Analysis by Company Size
9.4.3. Analysis by Location of Headquarters

10. CASE STUDY: AUTOINJECTOR-BASED COMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS
10.1. Chapter Overview
10.2. Marketed / Pipeline Autoinjector-based Combination Products
10.3. Case Study on Anaphylaxis
10.3.1. Overview and Epidemiology
10.3.2. Adrenaline: Mechanism of Action
10.3.3. History of Development
10.3.4. Marketed Adrenaline / Epinephrine Autoinjectors
10.3.4.1. Adrenaclick
10.3.4.2. Allerject / Auvi-Q (Formerly called e-cue)
10.3.4.3. Anapen
10.3.4.4. Emerade
10.3.4.5. EpiPen / EpiPen Jr
10.3.4.6. Jext
10.3.4.7. EpiPen / EpiPen Jr

10.3.5. Adrenaline / Epinephrine Autoinjectors Under Development
10.3.5.1. EpiQ
10.3.5.2. ANDIPen
10.3.5.3. MiniEpi
10.3.5.4. Zeneo Adrenaline

10.3.6. Other Dosage Forms
10.3.7. Historical Sales of Approved Drugs / Autoinjectors

10.4. Case Study II: Multiple Sclerosis
10.4.1. Overview and Epidemiology
10.4.2. Interferon β-1a
10.4.3. Interferon β-1b
10.4.4. Interferons: Mechanism of Action
10.4.5. History of Development
10.4.6. Interferon β-1a Autoinjectors
10.4.6.1. Avonex Pen
10.4.6.2. PLEGRIDY Pen
10.4.6.3. Rebif Rebidose
10.4.6.4. RebiSmart
10.4.6.5. Rebiject II
10.4.6.6. ReciGen Physioject

10.4.7. Interferon β-1b Autoinjectors
10.4.7.1. BETACONNECT
10.4.7.2. BETAJECT Comfort / Betacomfort
10.4.7.3. Betaject Lite
10.4.7.4. ExtaviJect 30G / ExtaviPro 30G

10.4.8. Other Marketed Autoinjectors
10.4.8.1. Cinnomer40 Physioject
10.4.8.2. CSYNC Autoinjector
10.4.8.3. WhisperJECT
10.4.8.4. Remurel Autoxon

10.4.9. Other Dosage Forms
10.4.10. Historical Sales of Approved Drugs / Autoinjectors
10.4.10.1. Interferon β-1a
10.4.10.2. Interferon β-1b
10.5. Case Study III: Migraine
10.5.1. Overview and Epidemiology
10.5.2. Sumatriptan Succinate: Mechanism of Action
10.5.3. History of Development
10.5.4. Marketed Autoinjectors
10.5.4.1. ALSUMA
10.5.4.2. IMITREX STATdose Pen
10.5.4.3. Zembrace SymTouch
10.5.4.4. Aimovig SureClick Autoinjector
10.5.4.5. Emgality Prefilled Pen

10.5.5. Other Dosage Forms
10.5.6. Historical Sales of Approved Drugs / Autoinjectors

10.6. Case Study IV: Rheumatoid Arthritis
10.6.1. Overview and Epidemiology
10.6.2. History of Development
10.6.3. Marketed Autoinjectors for Rheumatoid Arthritis
10.6.3.1. Actemra
10.6.3.2. CIMZIA AutoClicks Prefilled Pen
10.6.3.3. Enbrel SureClick
10.6.3.4. Hulio Prefilled Pen
10.6.3.5. HUMIRA Pen
10.6.3.6. ORENCIA ClickJect
10.6.3.7. OTREXUP
10.6.3.8. Rasuvo Autoinjector
10.6.3.9. SIMPONI SmartJect Autoinjector
10.6.3.10. KEVZARA Prefilled Pen
10.6.3.11. IMRALDI Prefilled Pen

10.6.4. Historical Sales of Approved Drugs / Autoinjectors

11. LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS
11.1. Chapter Overview
11.2. Methodology and Key Parameters
11.3. Marketed Drug Candidates for Delivery via Autoinjectors
11.3.1. Most Likely Drug Candidates
11.3.2. Likely Drug Candidates
11.3.3. Less Likely Drug Candidates
11.3.4. Unlikely Drug Candidates
11.4. Clinical Drug Candidates for Delivery via Autoinjectors
11.4.1. Most Likely Drug Candidates
11.4.2. Likely Drug Candidates
11.4.3. Less Likely Drug Candidates
11.4.4. Unlikely Drug Candidates

12. COMPANY PROFILES
12.1. Chapter Overview
12.2. Antares Pharma
12.2.1. Company Overview
12.2.2. Financial Information
12.2.3. Product Portfolio
12.2.3.1. Autoinjectors: Product Details
12.2.3.1.1. Vibex
12.2.3.1.2. QuickShot
12.2.3.1.3. BigShot

12.2.4. Collaborations
12.2.4.1. Teva Pharmaceutical
12.2.4.2. Ferring Pharmaceuticals
12.2.4.3. AMAG Pharmaceuticals
12.2.4.4. JCR Pharmaceuticals
12.2.4.5. Pfizer
12.2.4.6. Idorsia Pharmaceuticals
12.2.4.7. Lunatus Global Medical Supplies

12.2.5. Recent Developments and Future Outlook

12.3 Bespak (Acquired by Recipharm)
12.3.1. Company Overview
12.3.2. Financial Information
12.3.3. Technology Overview
12.3.4. Product Portfolio
12.3.4.1. Autoinjectors: Product Details
12.3.4.1.1. Syrina
12.3.4.1.2. OTS Autoinjector
12.3.4.1.3. Viscala Autoinjector

12.3.5. Collaborations
12.3.5.1. Undisclosed Global Biopharmaceutical Company
12.3.5.2. Regeneron Pharmaceuticals

12.3.6. Recent Developments and Future Outlook

12.4. DALI Medical Devices
12.4.1. Company Overview
12.4.2. Product Portfolio
12.4.2.1. Autoinjectors: Product Details
12.4.2.1.1. SAN-L
12.4.2.1.2. SAN-P
12.4.2.1.3. SAN-DV
12.4.2.1.4. SAN-DV Pro
12.2.2.1.5. SAN-Light

12.4.3. Collaborations
12.4.3.1. Elcam Drug Delivery Devices

12.4.4. Recent Developments and Future Outlook

12.5. Elcam Medical (E3D Elcam Drug Delivery Devices)
12.5.1. Company Overview
12.5.2. Product Portfolio
12.5.2.1. Autoinjectors: Product Details
12.5.2.1.1. Flexi-Q Disposable Autoinjectors
12.5.2.1.1.1. Flexi-Q PFS
12.5.2.1.1.2. Flexi-Q HV
12.5.2.1.1.3. Flexi -Q DV
12.5.2.1.1.4. Flexi-Q EAI
12.5.2.1.1.5. Flexi-Q CAI

12.5.2.1.2. Flexi-Q Reusable Autoinjectors
12.5.2.1.2.1. Flexi-Q mMU
12.5.2.1.2.2. Flexi-Q eMU-C / P

12.5.3. Comparison of Elcam Medical Autoinjectors
12.5.4. Collaborations
12.5.4.1. DALI Medical Devices
12.5.4.2. Jabil Healthcare

12.5.5. Recent Developments and Future Outlook

12.6. Jiangsu Delfu Medical Devices
12.6.1. Company Overview
12.6.2. Product Portfolio
12.6.2.1. Autoinjectors: Overview and Specifications
12.6.2.1.1. Components of Delfu Autoinjectors
12.6.2.1.2. Applications of Delfu Autoinjectors
12.6.2.1.3. Features of Delfu Autoinjectors
12.6.2.1.4. Advantages of Delfu Autoinjectors
12.6.2.1.5. Specifications of Delfu Autoinjectors

12.6.2.2. Autoinjectors: Product Details
12.6.2.2.1. YZ-II 3mL Cartridge Digital Dose Setting GF Autoinjector
12.6.2.2.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector
12.6.2.2.3. DZ-IA Auto Injector Pen
12.6.2.2.4. DZ-IA 3mL*0.1u Needle Hidden Smart VEGF Injection Pen
12.6.2.2.5. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen
12.6.3.2.6. YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors
12.6.3.2.7. YZ-III 0.001 mL Dose Accuracy Auto Injector Pen
12.6.3.2.8. YZ-II 3mL* 1u Auto Injector Pen
12.6.3.2.9. YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen
12.6.3.2.10. YZ-III Automatic Reusable Insulin Injection Pen

12.6.4. Recent Developments and Future Outlook

12.7. Oval Medical Technologies
12.7.1. Company Overview
12.7.2. Product Portfolio
12.7.2.1. Autoinjectors: Product Details
12.7.2.1.1 ArQ
12.7.2.1.2 ArQ-Bios
12.7.2.1.3 ArQ-Tempo
12.7.2.1.4 ArQ-Vita

12.7.3. Collaborations
12.7.3.1. SOLIZE

12.7.4. Recent Developments and Future Outlook

12.8. Owen Mumford
12.8.1. Company Overview
12.8.2. Product Portfolio
12.8.2.1. Autoinjectors: Product Details
12.8.2.1.1. Autoject Micro
12.8.2.1.2. Autoject 2
12.8.2.1.3. Autoject Mini
12.8.2.1.4. Autoject Visco
12.8.2.1.5. Autoject Uni
12.8.2.1.6. Autoject Multi
12.8.2.1.7. Autoject Flex
12.8.2.1.8. UniSafe Auto-injector
12.8.2.1.9. UniSafe Connected Auto-injector

12.8.3. Collaborations
12.8.3.1. Nipro
12.8.3.2. Sanofi Aventis

12.8.4. Recent Developments and Future Outlook

12.9. SHL Group
12.9.1. Company Overview
12.9.2. Product Portfolio
12.9.2.1. Two-Step Disposable Autoinjectors: Product Details
12.9.2.1.1 Amber (Pushclick Technology)
12.9.2.1.2. Molly
12.9.2.1.3. Molly RNS
12.9.2.1.4. Molly 2.25
12.9.2.1.5. Rotaject
12.9.2.1.6. Bertha
12.9.2.1.7. DAI 2
12.9.2.1.8. Maggie
12.9.2.1.9. Comparison of SHL Two-Step Autoinjectors

12.9.2.2. Three-Step Disposable Autoinjectors: Product Details
12.9.2.2.1. DAI
12.9.2.2.2. SDI-MIX+NIT (Needle Isolation Technology and Twist and Mix Mechanism)
12.9.2.2.3. VSDI+NIT
12.9.2.2.4. Comparison of SHL Three-Step Autoinjectors
12.9.2.3. PPI Injector (Rotaject Pressure Release Technology)
12.9.2.4. PenInject2.25

12.9.4. Collaborations
12.9.4.1. Schreiner MediPharm
12.9.4.2. QuiO

12.9.5. Recent Developments and Future Outlook

12.10. Union Medico
12.10.1. Company Overview
12.10.2. Technology Overview
12.10.3. Product Portfolio
12.10.3.1. Autoinjectors: Product Details
12.10.3.1.1 Semi 45? Autoinjector
12.10.3.1.2 Semi 45?/ S Autoinjector
12.10.3.1.3 Semi 45?/ M Autoinjector
12.10.3.1.4 Semi 45?/ R Autoinjector
12.10.3.1.5 Comparison of 45? Autoinjectors
12.10.3.1.6 90?Autoinjector
12.10.3.1.7 90?/ S Autoinjector
12.10.3.1.8 90?/ M Autoinjector
12.10.3.1.9 90?/ XL Autoinjector
12.10.3.1.10 SuperGrip Autoinjector
12.10.3.1.11 Exclusive Autoinjector
12.10.3.1.12 Comparison of 90? Autoinjectors

12.10.4. Recent Developments and Future Outlook

12.11. Ypsomed
12.11.1. Company Overview
12.11.2. Financial Information
12.11.3. Product Portfolio
12.11.3.1. Autoinjectors: Product details
12.11.3.1.1. YpsoMate, YpsoMate Zero, YpsoMate 2.25 and YpsoMate 2.25Pro
12.11.3.1.2. VarioJect
12.11.3.1.3. LyoTwist Trio, LyoTwist Trio S, LyoTwist Vario and LyoTwist Vario S
12.11.3.1.4. Comparison of Autoinjectors

12.11.4. Collaborations
12.11.4.1. Royal Philips
12.11.4.2. Teva

12.11.5. Recent Developments and Future Outlook

13. EMERGING PLAYERS
13.1. Chapter Overview
13.2. AktiVax
13.3. Amneal Pharmaceuticals
13.4. Kaléo
13.5. Nemera
13.6. Nuance Designs
13.7. Windgap Medical
13.8. Xeris Pharmaceuticals
13.9. Zion Clinical Pharmacy

14. KEY OPINION LEADERS (KOL) ANALYSIS
14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Principal Investigators Involved in Clinical Trials
14.3.1. Analysis by Type of Organization (KOL Affiliation)
14.3.2. Geographical Distribution of KOLs

14.4. Prominent KOLs
14.5. KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
14.6. Most Active KOLs
14.6.1. KOL Profile: A (Cedars-Sinai Medical Center)
14.6.2. KOL Profile: B (Mount Sinai Hospital)
14.6.3. KOL Profile: C (Magee-Womens Research Institute and Foundation)
14.6.4. KOL Profile: D (Imperial College London)
14.6.5. KOL Profile: E (Oslo University Hospital)

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Autoinjectors: List of Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Most Active Players: Analysis by Number of Partnerships
15.3.4. Regional Analysis
15.3.4.1 Intercontinental and Intracontinental Agreements

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Concluding Remarks

17. CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS
17.1. Chapter Overview
17.2. Challenges Associated with Medical Device Manufacturing
17.3. Role of CMOs in Medical Device Manufacturing
17.4. Services Offered by Medical Device CMOs
17.5. Advantages Offered by Medical Device CMOs
17.6. Risks Associated with Outsourcing to CMOs
17.7. Drug Delivery Device Service Providers
17.7.1. Analysis by Year of Establishment
17.7.2. Analysis by Company Size
17.7.3. Analysis by Geography
17.7.4. Analysis by Types of Services
17.8. Concluding Remarks

18. CASE STUDY: PREFILLED SYRINGES
18.1. Chapter Overview
18.2. Prefilled Syringes: List of Available / Under Development Devices
18.2.1. Analysis by Type of Barrel Fabrication Material
18.2.2. Analysis by Number of Barrel Chambers
18.2.3. Analysis by Type of Needle System
18.2.4. Analysis by Device Capacity

18.3. Prefilled Syringes: List of Developers
18.3.1. Analysis by Year of Establishment
18.3.2. Analysis by Company Size
18.3.3. Analysis by Geographical Location of Headquarters
18.3.4. Analysis by Geographical Location of Manufacturing Facilities

18.4. Technological Developments in Prefilled Syringes

19. GROWTH DRIVERS FOR PREFILLED SYRINGES
19.1. Chapter Overvie
19.2. Rising Incidence of Chronic Diseases
19.3. Growing Preference for Self-Injection
19.4 Evolving Patient Demographics
19.5 Growth of Biologics and Biosimilars Market
19.6 Changing Pharmaceutical Strategies
19.7 Increasing Focus on Prevention of Needlestick Injuries
19.8 Prefilled Syringes in Autoinjectors

20. MARKET SIZING AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Forecast Methodology and Key Assumptions
20.3. Global Autoinjectors Market, 2021-2030 (By Value)
20.3.1. Global Autoinjectors Market: Distribution by Usability, 2021-2030 (By Value)
20.3.2. Global Autoinjectors Market: Distribution by Route of Administration, 2021-2030 (By Value)
20.3.3. Global Autoinjectors Market: Distribution by Type of Molecule, 2021-2030 (By Value)

20.3.4. Autoinjectors Market in North America, 2021-2030 (By Value)
20.3.4.1. Autoinjectors Market in North America: Distribution by Usability, 2021-2030 (By Value)
20.3.4.2. Autoinjectors Market in North America: Distribution by Route of Administration, 2021-2030 (By Value)
20.3.4.3. Autoinjectors Market in North America: Distribution by Type of Molecule, 2021-2030 (By Value)

20.3.5. Autoinjectors Market in Europe, 2021-2030 (By Value)
20.3.5.1. Autoinjectors Market in Europe: Distribution by Usability, 2021-2030 (By Value)
20.3.5.2. Autoinjectors Market in Europe: Distribution by Route of Administration, 2021-2030 (By Value)
20.3.5.3. Autoinjectors Market in Europe: Distribution by Type of Molecule, 2021-2030 (By Value)

20.3.6. Autoinjectors Market in Asia Pacific, 2021-2030 (By Value)
19.3.6.1. Autoinjectors Market in Asia Pacific: Distribution by Usability, 2021-2030 (By Value)
20.3.6.2. Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Value)
20.3.6.3. Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Value)

20.3.7. Autoinjectors Market in Rest of the World, 2021-2030 (By Value)
20.3.7.1. Autoinjectors Market in Rest of the World: Distribution by Usability, 2021-2030 (By Value)
20.3.7.2. Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Value)
20.3.7.3. Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Value)

20.4. Global Autoinjectors Market, 2021-2030 (By Volume)
20.4.1. Global Autoinjectors Market: Distribution by Usability, 2021-2030 (By Volume)
20.4.2. Global Autoinjectors Market: Distribution by Route of Administration, 2021-2030 (By Volume)
20.4.3. Global Autoinjectors Market: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.4.4. Autoinjectors Market in North America, 2021-2030 (By Volume)
20.3.4.1. Autoinjectors Market in North America: Distribution by Usability, 2021-2030 (By Volume)
20.3.4.2. Autoinjectors Market in North America: Distribution by Route of Administration, 2021-2030 (By Volume)
20.3.4.3. Autoinjectors Market in North America: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.3.5. Autoinjectors Market in Europe, 2021-2030 (By Volume)
20.3.5.1. Autoinjectors Market in Europe: Distribution by Usability, 2021-2030 (By Volume)
20.3.5.2. Autoinjectors Market in Europe: Distribution by Route of Administration, 2021-2030 (By Volume)
20.3.5.3. Autoinjectors Market in Europe: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.3.6. Autoinjectors Market in Asia Pacific, 2021-2030 (By Volume)
20.3.6.1. Autoinjectors Market in Asia Pacific: Distribution by Usability, 2021-2030 (By Volume)
20.3.6.2. Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Volume)
20.3.6.3. Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.3.7. Autoinjectors Market in Rest of the World, 2021-2030 (By Volume)
20.3.7.1. Autoinjectors Market in Rest of the World: Distribution by Usability, 2021-2030 (By Volume)
20.3.7.2. Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Volume)
20.3.7.3. Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.5. Global Autoinjectors Market for Anaphylaxis, 2021-2030 (By Value)
20.5.1. Autoinjectors Market for Anaphylaxis in North America, 2021-2030 (By Value)
20.5.1.1. Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2021-2030 (By Value)
20.5.1.2. Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2021-2030 (By Value)
20.5.1.3. Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2021-2030 (By Value)

20.5.2. Autoinjectors Market for Anaphylaxis in Europe, 2021-2030 (By Value)
20.5.2.1. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2021-2030 (By Value)
20.5.2.2. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2021-2030 (By Value)
20.5.2.3. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2021-2030 (By Value)

20.5.3. Autoinjectors Market for Anaphylaxis in Asia Pacific, 2021-2030 (By Value)
20.5.3.1. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2021-2030 (By Value)
20.5.3.2. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Value)
20.5.3.3. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Value)
20.5.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2030 (By Value)
20.5.4.1. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2021-2030 (By Value)
20.5.4.2. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Value)
20.5.4.3. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Value)

20.6. Global Autoinjectors Market for Anaphylaxis, 2021-2030 (By Volume)
20.6.1. Autoinjectors Market for Anaphylaxis in North America, 2021-2030 (By Volume)
20.6.1.1. Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2021-2030 (By Volume)
20.6.1.2. Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2021-2030 (By Volume)
20.6.1.3. Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.6.2. Autoinjectors Market for Anaphylaxis in Europe, 2021-2030 (By Volume)
20.6.2.1. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2021-2030 (By Volume)
20.6.2.2. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2021-2030 (By Volume)
20.6.2.3. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.6.3. Autoinjectors Market for Anaphylaxis in Asia Pacific, 2021-2030 (By Volume)
20.6.3.1. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2021-2030 (By Volume)
20.6.3.2. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Volume)
20.6.3.3. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.6.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2030 (By Volume)
20.6.4.1. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2021-2030 (By Volume)
20.6.4.2. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Volume)
20.6.4.3. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.7. Global Autoinjectors Market for Multiple Sclerosis, 2021-2030 (By Value)
20.7.1. Autoinjectors Market for Multiple Sclerosis in North America, 2021-2030 (By Value)
20.7.1.1. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2021-2030 (By Value)
20.7.1.2. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2021-2030 (By Value)
20.7.1.3. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2021-2030 (By Value)

20.7.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2030 (By Value)
20.7.2.1. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2021-2030 (By Value)
20.7.2.2. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2021-2030 (By Value)
20.7.2.3. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2021-2030 (By Value)

20.7.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2021-2030 (By Value)
20.7.3.1. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2021-2030 (By Value)
20.7.3.2. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Value)
20.7.3.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Value)

20.7.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2030 (By Value)
20.7.4.1. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2021-2030 (By Value)
20.7.4.2. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Value)
20.7.4.3. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Value)

20.8. Global Autoinjectors Market for Multiple Sclerosis, 2021-2030 (By Volume)
20.8.1. Autoinjectors Market for Multiple Sclerosis in North America, 2021-2030 (By Volume)
20.8.1.1. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2021-2030 (By Volume)
20.8.1.2. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2021-2030 (By Volume)
20.8.1.3. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.8.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2030 (By Volume)
20.8.2.1. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2021-2030 (By Volume)
20.8.2.2. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2021-2030 (By Volume)
20.8.2.3. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.8.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2021-2030 (By Volume)
20.8.3.1. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2021-2030 (By Volume)
20.8.3.2. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Volume)
20.8.3.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.8.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2030 (By Volume)
20.8.4.1. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2021-2030 (By Volume)
20.8.4.2. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Volume)
20.8.4.3. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.9. Global Autoinjectors Market for Rheumatoid Arthritis, 2021-2030 (By Value)
20.9.1. Autoinjectors Market for Rheumatoid Arthritis in North America, 2021-2030 (By Value)
20.9.1.1. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2021-2030 (By Value)
20.9.1.2. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2021-2030 (By Value)
20.9.1.3. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2021-2030 (By Value)

20.9.2. Autoinjectors Market for Rheumatoid Arthritis in Europe, 2021-2030 (By Value)
20.9.2.1. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2021-2030 (By Value)
20.9.2.2. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2021-2030 (By Value)
20.9.2.3. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2021-2030 (By Value)

20.9.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2021-2030 (By Value)
20.9.3.1. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2021-2030 (By Value)
20.9.3.2. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Value)
20.9.3.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Value)
20.9.4. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2021-2030 (By Value)
20.9.4.1. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2021-2030 (By Value)
20.9.4.2. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Value)
20.9.4.3. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Value)

20.10. Global Autoinjectors Market for Rheumatoid Arthritis, 2021-2030 (By Volume)
20.10.1. Autoinjectors Market for Rheumatoid Arthritis in North America, 2021-2030 (By Volume)
20.10.1.1. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2021-2030 (By Volume)
20.10.1.2. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2021-2030 (By Volume)
20.10.1.3. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.10.2. Autoinjectors Market for Rheumatoid Arthritis in Europe, 2021-2030 (By Volume)
20.10.2.1. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2021-2030 (By Volume)
20.10.2.2. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2021-2030 (By Volume)
20.10.2.3. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2021-2030 (By Volume)
20.10.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2021-2030 (By Volume)
20.10.3.1. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2021-2030 (By Volume)
20.10.3.2. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Volume)
20.10.3.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.10.4. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2021-2030 (By Volume)
20.10.4.1. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2021-2030 (By Volume)
20.10.4.2. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Volume)
20.10.4.3. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.11. Global Autoinjectors Market for Migraine, 2021-2030 (By Value)
20.11.1. Autoinjectors Market for Migraine in North America, 2021-2030 (By Value)
20.11.1.1. Autoinjectors Market for Migraine in North America: Distribution by Usability, 2021-2030 (By Value)
20.11.1.2. Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2021-2030 (By Value)
20.11.1.3. Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2021-2030 (By Value)

20.11.2. Autoinjectors Market for Migraine in Europe, 2021-2030 (By Value)
20.11.2.1. Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2021-2030 (By Value)
20.11.2.2. Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2021-2030 (By Value)
20.11.2.3. Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2021-2030 (By Value)

20.11.3. Autoinjectors Market for Migraine in Asia Pacific, 2021-2030 (By Value)
20.11.3.1. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2021-2030 (By Value)
20.11.3.2. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Value)
20.11.3.3. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Value)

20.11.4. Autoinjectors Market for Migraine in Rest of the World, 2021-2030 (By Value)
20.11.4.1. Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2021-2030 (By Value)
20.11.4.2. Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Value)
20.11.4.3. Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Value)

20.12. Global Autoinjectors Market for Migraine, 2021-2030 (By Volume)
20.12.1. Autoinjectors Market for Migraine in North America, 2021-2030 (By Volume)
20.12.1.1. Autoinjectors Market for Migraine in North America: Distribution by Usability, 2021-2030 (By Volume)
20.12.1.2. Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2021-2030 (By Volume)
20.12.1.3. Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.12.2. Autoinjectors Market for Migraine in Europe, 2021-2030 (By Volume)
20.12.2.1. Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2021-2030 (By Volume)
20.12.2.2. Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2021-2030 (By Volume)
20.12.2.3. Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.12.3. Autoinjectors Market for Migraine in Asia Pacific, 2021-2030 (By Volume)
20.12.3.1. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2021-2030 (By Volume)
20.12.3.2. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Volume)
20.12.3.3. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.12.4. Autoinjectors Market for Migraine in Rest of the World, 2021-2030 (By Volume)
20.12.4.1. Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2021-2030 (By Volume)
20.12.4.2. Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Volume)
20.12.4.3. Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.13. Global Autoinjectors Market for Diabetes, 2021-2030 (By Value)
20.13.1. Autoinjectors Market for Diabetes in North America, 2021-2030 (By Value)
20.13.1.1. Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2021-2030 (By Value)
20.13.1.2. Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2021-2030 (By Value)
20.13.1.3. Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2021-2030 (By Value)

20.13.2. Autoinjectors Market for Diabetes in Europe, 2021-2030 (By Value)
20.13.2.1. Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2021-2030 (By Value)
20.13.2.2. Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2021-2030 (By Value)
20.13.2.3. Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2021-2030 (By Value)

20.13.3. Autoinjectors Market for Diabetes in Asia Pacific, 2021-2030 (By Value)
20.13.3.1. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2021-2030 (By Value)
20.13.3.2. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Value)
20.13.3.3. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Value)

20.13.4. Autoinjectors Market for Diabetes in Rest of the World, 2021-2030 (By Value)
20.13.4.1. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2021-2030 (By Value)
20.13.4.2. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Value)
20.13.4.3. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Value)

20.14. Global Autoinjectors Market for Diabetes, 2021-2030 (By Volume)
20.14.1. Autoinjectors Market for Diabetes in North America, 2021-2030 (By Volume)
20.14.1.1. Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2021-2030 (By Volume)
20.14.1.2. Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2021-2030 (By Volume)
20.14.1.3. Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.14.2. Autoinjectors Market for Diabetes in Europe, 2021-2030 (By Volume)
20.14.2.1. Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2021-2030 (By Volume)
20.14.2.2. Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2021-2030 (By Volume)
20.14.2.3. Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.14.3. Autoinjectors Market for Diabetes in Asia Pacific, 2021-2030 (By Volume)
20.14.3.1. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2021-2030 (By Volume)
20.14.3.2. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Volume)
20.14.3.3. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.14.4. Autoinjectors Market for Diabetes in Rest of the World, 2021-2030 (By Volume)
20.14.4.1. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2021-2030 (By Volume)
20.14.4.2. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Volume)
20.14.4.3. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Volume)
20.15. Global Autoinjectors Market for Other Indications, 2021-2030 (By Value)
20.15.2. Autoinjectors Market for Other Indications in North America, 2021-2030 (By Value)
20.15.2.1. Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2021-2030 (By Value)
20.15.2.2. Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2021-2030 (By Value)
20.15.2.3. Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2021-2030 (By Value)

20.15.3. Autoinjectors Market for Other Indications in Europe, 2021-2030 (By Value)
20.15.3.1. Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2021-2030 (By Value)
20.15.3.2. Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2021-2030 (By Value)
20.15.3.3. Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2021-2030 (By Value)

20.15.4. Autoinjectors Market for Other Indications in Asia Pacific, 2021-2030 (By Value)
20.15.4.1. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2021-2030 (By Value)
20.15.4.2. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Value)
20.15.4.3. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Value)

20.15.5. Autoinjectors Market for Other Indications in Rest of the World, 2021-2030 (By Value)
20.15.5.1. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2021-2030 (By Value)
20.15.5.2. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Value)
20.15.5.3. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Value)

20.16. Global Autoinjectors Market for Other Indications, 2021-2030 (By Volume)
20.16.1. Autoinjectors Market for Other Indications in North America, 2021-2030 (By Volume)
20.16.1.1. Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2021-2030 (By Volume)
20.16.1.2. Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2021-2030 (By Volume)
20.16.1.3. Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.16.2. Autoinjectors Market for Other Indications in Europe, 2021-2030 (By Volume)
20.16.2.1. Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2021-2030 (By Volume)
20.16.2.2. Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2021-2030 (By Volume)
20.16.2.3. Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.16.3. Autoinjectors Market for Other Indications in Asia Pacific, 2021-2030 (By Volume)
20.16.3.1. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2021-2030 (By Volume)
20.16.3.2. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2021-2030 (By Volume)
20.16.3.3. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (By Volume)

20.16.4. Autoinjectors Market for Other Indications in Rest of the World, 2021-2030 (By Volume)
20.16.4.1. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2021-2030 (By Volume)
20.16.4.2. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2021-2030 (By Volume)
20.16.4.3. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2021-2030 (By Volume)

21. EXECUTIVE INSIGHTS
21.1. Chapter Overview
21.2. DALI Medical Devices
21.2.1. Company Snapshot
21.2.2. Interview Transcript: David Daily, Chief Executive Officer and Co-Founder

21.3. Oval Medical Technologies
21.3.1. Company Snapshot
21.3.2. Interview Transcript: Barbara Lead, Chief Executive Officer

21.4. Duoject Medical Systems
21.4.1. Company Snapshot
21.4.2. Interview Transcript: William G. Fortina, Business Development Director, Drug Delivery Systems

21.5. PHC
21.5.1. Company Snapshot
21.5.2. Interview Transcript: Douglas Marenzi, Managing Director

21.6. Elcam Medical
21.6.1. Company Snapshot
21.6.2. Interview Transcript: Tsachi Shaked, Senior Marketing and BD Director, Injectable Drug Delivery Devices

21.7. IDEO
21.7.1. Company Snapshot
21.7.2. Interview Transcript: Jesse Fourt, Design Director

21.8. Bill & Melinda Gates Foundation
21.8.1. Company Snapshot
21.8.2. Interview Transcript: Dennis Lee, Senior Program Officer in CMC

22. CONCLUDING REMARKS
22.1. Chapter Overview

23. APPENDIX 1: TABULATED DATA

24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Popular Drug Delivery Systems
Figure 3.2 Types of Self-Injection Devices
Figure 3.3 Components of an Autoinjector
Figure 3.4 Cartridge Based Autoinjectors versus Prefilled Syringe Based Autoinjectors
Figure 3.5 Classification of Autoinjectors
Figure 5.1 Autoinjectors: Distribution by Usability
Figure 5.2 Autoinjectors: Distribution by Type of Primary Container
Figure 5.3 Autoinjectors: Distribution by Volume of Container
Figure 5.4 Autoinjectors: Distribution by Type of Dose
Figure 5.5 Autoinjectors: Distribution by Route of Administration
Figure 5.6 Autoinjectors: Distribution by Actuation Mechanism
Figure 5.7 Autoinjectors: Distribution by Type of Feedback Mechanism
Figure 5.8 Autoinjector Developers: Distribution by Year of Establishment
Figure 5.9 Autoinjector Developers: Distribution by Company Size
Figure 5.10 Autoinjector Developers: Distribution by Geographical Location of Headquarters
Figure 6.1 Competitiveness Analysis: Disposable Autoinjectors
Figure 6.2 Competitiveness Analysis: Reusable Autoinjectors
Figure 7.1 Brand Positioning Analysis of Key Industrial Players: Competitive Advantage
Figure 7.2 Brand Positioning Analysis of Key Industrial Players: Reasons to Believe
Figure 7.3 Brand Positioning Matrix: Antares Pharma
Figure 7.4 Brand Positioning Matrix: Becton Dickinson
Figure 7.5 Brand Positioning Matrix: Bespak
Figure 7.6 Brand Positioning Matrix: DALI Medical Devices
Figure 7.7 Brand Positioning Matrix: Elcam Medical
Figure 7.8 Brand Positioning Matrix: Jiangsu Delfu medical device
Figure 7.9 Brand Positioning Matrix: Kaleo
Figure 7.10 Brand Positioning Matrix: Oval Medical Technologies
Figure 7.11 Brand Positioning Matrix: Owen Mumford
Figure 7.12 Brand Positioning Matrix: Pharma Consult
Figure 7.13 Brand Positioning Matrix: SHL Medical
Figure 7.14 Brand Positioning Matrix: Union Medico
Figure 7.15 Brand Positioning Matrix: Ypsomed
Figure 8.1 Patent Analysis: Distribution by Type of Patent
Figure 8.2 Patent Analysis: Cumulative Distribution by Publication Year
Figure 8.3 Patent Analysis: Distribution by Geography
Figure 8.4 Patent Analysis: Distribution by CPC Symbols
Figure 8.5 Patent Analysis: Emerging Focus Areas
Figure 8.6 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Figure 8.7 Leading Industry Players: Distribution by Number of Patents
Figure 8.8 Patent Analysis (Leading Industry Players): Benchmarking by Patent Characteristics (CPC Symbols)
Figure 8.9 Patent Analysis: Distribution of Patents by Age (2015-2021)
Figure 8.10 Autoinjectors: Patent Valuation
Figure 9.1 Approved Autoinjector Combination Products: Cumulative Number of Approvals by Initial Year of Approval
Figure 9.2 Approved Autoinjector Combination Products: Distribution by Usability
Figure 9.3 Approved Autoinjector Combination Products: Distribution by Route of Administration
Figure 9.4 Approved Autoinjector Combination Products: Distribution by Primary Drug Container
Figure 9.5 Approved Autoinjector Combination Products: Distribution by Type of Molecule
Figure 9.6 Approved Autoinjector Combination Products: Distribution by Dose Strength
Figure 9.7 Approved Autoinjector Combination Products: Distribution by Therapeutic Indication
Figure 9.8 Approved Autoinjector Combination Products: Distribution by Other Packaging Formats of Marketed Drugs
Figure 9.9 Pipeline Autoinjector Combination Products: Distribution by Phase of Development
Figure 9.10 Pipeline Autoinjector Combination Products: Distribution by Route of Administration
Figure 9.11 Pipeline Autoinjector Combination Products: Distribution by Type of Molecule
Figure 9.12 Pipeline Autoinjector Combination Products: Distribution by Therapeutic Indication
Figure 9.13 Grid Analysis: Distribution by Therapeutics Indication, Phase of Development and Route of Administration
Figure 9.14 Autoinjector Combination Product Developers: Distribution by Year of Establishment
Figure 9.15 Autoinjector Combination Product Developers: Distribution by Company Size
Figure 9.16 Autoinjector Combination Product Developers: Distribution by Geographical Location of Headquarters
Figure 10.1 Anaphylaxis: History of Drug Development
Figure 10.2 EpiPen: Historical Drug Sales (USD Billion), 2012-2017
Figure 10.3 Multiple Sclerosis: History of Drug Development
Figure 10.4 Interferon β-1a: Historical Sales (USD Billion), 2014-2020
Figure 10.5 Interferon β-1b: Historical Sales (USD Million), 2014-2020
Figure 10.6 Migraine: History of Drug Development
Figure 10.7 Migraine: Historical Drug Sales (USD Million), 2014-2020
Figure 10.8 Rheumatoid Arthritis: History of Drug Development
Figure 10.9 Rheumatoid Arthritis: Historical Drug Sales (USD Billion), 2014-2020
Figure 11.1 Likely Drug Candidates: Marketed Drugs
Figure 11.2 Likely Drug Candidates: Pipeline Drugs
Figure 12.1 Antares Pharma: Annual Revenues, 2014-H1 2021 (USD Million)
Figure 12.2 Antares Pharma: Product Portfolio
Figure 12.3 Consort Medical: Annual Revenues, 2014-2019 (GBP Million)
Figure 12.4 Bespak Injectables: Syrina Autoinjectors
Figure 12.5 DALI Medical Devices: Autoinjectors
Figure 12.6 SAN-L: Mechanism of Drug Delivery
Figure 12.7 SAN-P: Mechanism of Drug Delivery
Figure 12.8 SAN-DV: Mechanism of Drug Delivery
Figure 12.9 SAN-DV Pro: Mechanism of Drug Delivery
Figure 12.10 SAN-Light: Mechanism of Drug Delivery
Figure 12.11 Elcam Medical: Product Portfolio
Figure 12.12 Elcam Medical: Flexi-Q Autoinjectors
Figure 12.13 Flexi-Q PFS: Components
Figure 12.14 Flexi-Q PFS: Mechanism of Drug Delivery
Figure 12.15 Flexi-Q DV: Components
Figure 12.16 Flexi-Q DV: Mechanism of Drug Delivery
Figure 12.17 Flexi-Q mMU: Components
Figure 12.18 Flexi-Q eMU: Components
Figure 12.19 Flexi-Q mMU / Flexi-Q eMU: Mechanism of Drug Delivery
Figure 12.20 Flexi-Q EAI: Mechanism of Drug Delivery
Figure 12.21 Delfu Autoinjectors: Components
Figure 12.22 Applications of Delfu Autoinjectors
Figure 12.23 Oval Medical Technologies: Product Portfolio
Figure 12.24 ArQ: Mechanism of Drug Delivery
Figure 12.25 ArQ-Bios: Mechanism of Drug Delivery
Figure 12.26 ArQ-Tempo: Mechanism of Drug Delivery
Figure 12.27 ArQ-Vita: Mechanism of Drug Delivery
Figure 12.28 Owen Mumford: Product Portfolio
Figure 12.29 Autoject Micro: Mechanism of Drug Delivery
Figure 12.30 Autoject 2 Autoinjector: Mechanism of Drug Delivery
Figure 12.31 Autoject Mini: Mechanism of Drug Delivery
Figure 12.32 SHL Medical: Product Portfolio
Figure 12.33 SHL Medical: Prefilled Syringe Based Autoinjectors
Figure 12.34 SHL Medical: Cartridge Based Autoinjectors
Figure 12.35 SHL Medical: Two-Step Autoinjectors
Figure 12.36 SHL Medical Two-Step Autoinjectors: Mechanism of Drug Delivery
Figure 12.37 SHL Medical: Three-Step Autoinjectors
Figure 12.38 DAI: Mechanism of Drug Delivery
Figure 12.39 SDI-MIX+NIT: Mechanism of Drug Delivery
Figure 12.40 Union Medico: 45?Autoinjector Portfolio
Figure 12.41 Union Medico: Parts of 45?/R Autoinjector
Figure 12.42 Union Medico: Types of 45?/R Autoinjector
Figure 12.43 Union Medico: Types of 90? Autoinjectors
Figure 12.44 Exclusive: Components
Figure 12.45 Ypsomed: Annual Revenues, 2014-15 - 2020-21 (CHF Million)
Figure 12.46 Ypsomed: Product Portfolio
Figure 12.47 YpsoMate: Mechanism of Drug Delivery
Figure 12.48 VarioJect: Mechanism of Drug Delivery
Figure 14.1 Geographical Distribution of Principal Investigators
Figure 14.2 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Figure 14.3 Geographical Distribution of Patent Applicants
Figure 15.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2014-2021
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Cumulative Trend by Year and Type of Partnership, 2014-2021
Figure 15.4 Most Active Players: Distribution by Number of Partnerships
Figure 15.5 Partnerships and Collaborations: Regional Distribution
Figure 15.6 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 16.1 Autoinjectors SWOT Analysis: Overview
Figure 16.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 17.1 Challenges Associated with Medical Device Manufacturing
Figure 17.2 Services Offered by Medical Device CMOs
Figure 17.3 Advantages of Outsourcing to CMOs
Figure 17.4 Risks Associated with Outsourcing to CMOs
Figure 17.5 Drug Delivery Device Service Providers: Distribution by Year of Establishment
Figure 17.6 Drug Delivery Device Service Providers: Distribution by Company Size
Figure 17.7 Drug Delivery Device Service Providers: Distribution by Geography
Figure 17.8 Drug Delivery Device Service Providers: Distribution by Types of Services
Figure 18.1 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Figure 18.2 Prefilled Syringes: Distribution by Number of Barrel Chambers
Figure 18.3 Prefilled Syringes: Distribution by Type of Needle System
Figure 18.4 Prefilled Syringes: Distribution by Device Capacity
Figure 18.5 Prefilled Syringe Developers: Distribution by Year of Establishment
Figure 18.6 Prefilled Syringe Developers: Distribution by Company Size
Figure 18.7 Prefilled Syringe Developers: Distribution by Geographical Location of Headquarters
Figure 18.8 Prefilled Syringe Developers: Distribution by Geographical Location of Manufacturing Facilities
Figure 18.9 Technological Evolution of Prefilled Syringes
Figure 19.1 Global Autoinjectors Market, 2021-2030 (USD Million)
Figure 19.2 Global Autoinjectors Market: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.3 Global Autoinjectors Market: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.4 Autoinjectors Market in North America, 2021-2030 (USD Million)
Figure 19.5 Autoinjectors Market in North America: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.6 Autoinjectors Market in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.7 Autoinjectors Market in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.8 Autoinjectors Market in Europe, 2021-2030 (USD Million)
Figure 19.9 Autoinjectors Market in Europe: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.10 Autoinjectors Market in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.11 Autoinjectors Market in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.12 Autoinjectors Market in Asia Pacific, 2021-2030 (USD Million)
Figure 19.13 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.14 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.15 Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.16 Autoinjectors Market in Rest of the World, 2021-2030 (USD Million)
Figure 19.17 Autoinjectors Market in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.18 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.19 Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.20 Global Autoinjectors Market, 2021-2030 (Units, Million)
Figure 19.21 Global Autoinjectors Market: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.22 Global Autoinjectors Market: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.23 Global Autoinjectors Market: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.24 Autoinjectors Market in North America, 2021-2030 (Units, Million)
Figure 19.25 Autoinjectors Market in North America: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.26 Autoinjectors Market in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.27 Autoinjectors Market in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.28 Autoinjectors Market in Europe, 2021-2030 (Units, Million)
Figure 19.29 Autoinjectors Market in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.30 Autoinjectors Market in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.31 Autoinjectors Market in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.32 Autoinjectors Market in Asia Pacific, 2021-2030 (Units, Million)
Figure 19.33 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.34 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.35 Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.36 Autoinjectors Market in Rest of the World, 2021-2030 (Units, Million)
Figure 19.37 Autoinjectors Market in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.38 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.39 Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.40 Global Autoinjectors Market for Anaphylaxis, 2021-2030 (USD Million)
Figure 19.41 Autoinjectors Market for Anaphylaxis in North America, 2021-2030 (USD Million)
Figure 19.42 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.43 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.44 Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.45 Autoinjectors Market for Anaphylaxis in Europe, 2021-2030 (USD Million)
Figure 19.46 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.47 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.48 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.49 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2021-2030 (USD Million)
Figure 19.50 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.51 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.52 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.53 Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2030 (USD Million)
Figure 19.54 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.55 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.56 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.57 Global Autoinjectors Market for Anaphylaxis, 2021-2030 (Units, Million)
Figure 19.58 Autoinjectors Market for Anaphylaxis in North America, 2021-2030 (Units, Million)
Figure 19.59 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.60 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.61 Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.62 Autoinjectors Market for Anaphylaxis in Europe, 2021-2030 (Units, Million)
Figure 19.63 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.64 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.65 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.66 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2021-2030 (Units, Million)
Figure 19.67 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.68 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.69 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.70 Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2030 (Units, Million)
Figure 19.71 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.72 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.73 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.74 Global Autoinjectors Market for Multiple Sclerosis, 2021-2030 (USD Million)
Figure 19.75 Autoinjectors Market for Multiple Sclerosis in North America, 2021-2030 (USD Million)
Figure 19.76 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.77 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.78 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.79 Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2030 (USD Million)
Figure 19.80 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.81 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.82 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.83 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2021-2030 (USD Million)
Figure 19.84 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.85 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.86 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.87 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2030 (USD Million)
Figure 19.88 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.89 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.90 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.91 Global Autoinjectors Market for Multiple Sclerosis, 2021-2030 (Units, Million)
Figure 19.92 Autoinjectors Market for Multiple Sclerosis in North America, 2021-2030 (Units, Million)
Figure 19.93 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.94 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.95 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.96 Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2030 (Units, Million)
Figure 19.97 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.98 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.99 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.100 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2021-2030 (Units, Million)
Figure 19.101 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.102 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.103 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.104 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2030 (Units, Million)
Figure 19.105 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.106 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.107 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.108 Global Autoinjectors Market for Rheumatoid Arthritis, 2021-2030 (USD Million)
Figure 19.109 Autoinjectors Market for Rheumatoid Arthritis in North America, 2021-2030 (USD Million)
Figure 19.110 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.111 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.112 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.113 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2021-2030 (USD Million)
Figure 19.114 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.115 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.116 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.117 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2021-2030 (USD Million)
Figure 19.118 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.119 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.120 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.121 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2021-2030 (USD Million)
Figure 19.122 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.123 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.124 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.125 Global Autoinjectors Market for Rheumatoid Arthritis, 2021-2030 (Units, Million)
Figure 19.126 Autoinjectors Market for Rheumatoid Arthritis in North America, 2021-2030 (Units, Million)
Figure 19.127 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.128 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.129 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.130 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2021-2030 (Units, Million)
Figure 19.131 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.132 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.133 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.134 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2021-2030 (Units, Million)
Figure 19.135 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.136 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.137 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.138 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2021-2030 (Units, Million)
Figure 19.139 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.140 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.141 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.142 Global Autoinjectors Market for Migraine, 2021-2030 (USD Million)
Figure 19.143 Autoinjectors Market for Migraine in North America, 2021-2030 (USD Million)
Figure 19.144 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.145 Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.146 Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.147 Autoinjectors Market for Migraine in Europe, 2021-2030 (USD Million)
Figure 19.148 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.149 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.150 Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.151 Autoinjectors Market for Migraine in Asia Pacific, 2021-2030 (USD Million)
Figure 19.152 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.153 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.154 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.155 Autoinjectors Market for Migraine in Rest of the World, 2021-2030 (USD Million)
Figure 19.156 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.157 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.158 Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.159 Global Autoinjectors Market for Migraine, 2021-2030 (Units, Million)
Figure 19.160 Autoinjectors Market for Migraine in North America, 2021-2030 (Units, Million)
Figure 19.161 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.162 Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.163 Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.164 Autoinjectors Market for Migraine in Europe, 2021-2030 (Units, Million)
Figure 19.165 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.166 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.167 Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.168 Autoinjectors Market for Migraine in Asia Pacific, 2021-2030 (Units, Million)
Figure 19.169 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.170 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.171 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.172 Autoinjectors Market for Migraine in Rest of the World, 2021-2030 (Units, Million)
Figure 19.173 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.174 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.175 Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.176 Global Autoinjectors Market for Diabetes, 2021-2030 (USD Million)
Figure 19.177 Autoinjectors Market for Diabetes in North America, 2021-2030 (USD Million)
Figure 19.178 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.179 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.180 Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.181 Autoinjectors Market for Diabetes in Europe, 2021-2030 (USD Million)
Figure 19.182 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.183 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.184 Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.185 Autoinjectors Market for Diabetes in Asia Pacific, 2021-2030 (USD Million)
Figure 19.186 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.187 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.188 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.189 Autoinjectors Market for Diabetes in Rest of the World, 2021-2030 (USD Million)
Figure 19.190 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.191 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.192 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.193 Global Autoinjectors Market for Diabetes, 2021-2030 (Units, Million)
Figure 19.194 Autoinjectors Market for Diabetes in North America, 2021-2030 (Units, Million)
Figure 19.195 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.196 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.197 Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.198 Autoinjectors Market for Diabetes in Europe, 2021-2030 (Units, Million)
Figure 19.199 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.200 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.201 Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.202 Autoinjectors Market for Diabetes in Asia Pacific, 2021-2030 (Units, Million)
Figure 19.203 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.204 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.205 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.206 Autoinjectors Market for Diabetes in Rest of the World, 2021-2030 (Units, Million)
Figure 19.207 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.208 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.209 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.210 Global Autoinjectors Market for Asthma, 2021-2030 (USD Thousand)
Figure 19.211 Autoinjectors Market for Asthma in North America, 2021-2030 (USD Thousand)
Figure 19.212 Autoinjectors Market for Asthma in North America: Distribution by Usability, 2021-2030 (USD Thousand)
Figure 19.213 Autoinjectors Market for Asthma in North America: Distribution by Route of Administration, 2021-2030 (USD Thousand)
Figure 19.214 Autoinjectors Market for Asthma in North America: Distribution by Type of Molecule, 2021-2030 (USD Thousand)
Figure 19.215 Autoinjectors Market for Asthma in Europe, 2021-2030 (USD Thousand)
Figure 19.216 Autoinjectors Market for Asthma in Europe: Distribution by Usability, 2021-2030 (USD Thousand)
Figure 19.217 Autoinjectors Market for Asthma in Europe: Distribution by Route of Administration, 2021-2030 (USD Thousand)
Figure 19.218 Autoinjectors Market for Asthma in Europe: Distribution by Type of Molecule, 2021-2030 (USD Thousand)
Figure 19.219 Autoinjectors Market for Asthma in Asia Pacific, 2021-2030 (USD Thousand)
Figure 19.220 Autoinjectors Market for Asthma in Asia Pacific: Distribution by Usability, 2021-2030 (USD Thousand)
Figure 19.221 Autoinjectors Market for Asthma in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Thousand)
Figure 19.222 Autoinjectors Market for Asthma in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Thousand)
Figure 19.223 Autoinjectors Market for Asthma in Rest of the World, 2021-2030 (USD Thousand)
Figure 19.224 Autoinjectors Market for Asthma in Rest of the World: Distribution by Usability, 2021-2030 (USD Thousand)
Figure 19.225 Autoinjectors Market for Asthma in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Thousand)
Figure 19.226 Autoinjectors Market for Asthma in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Thousand)
Figure 19.227 Global Autoinjectors Market for Asthma, 2021-2030 (Units, Thousand)
Figure 19.228 Autoinjectors Market for Asthma in North America, 2021-2030 (Units, Thousand)
Figure 19.229 Autoinjectors Market for Asthma in North America: Distribution by Usability, 2021-2030 (Units, Thousand)
Figure 19.230 Autoinjectors Market for Asthma in North America: Distribution by Route of Administration, 2021-2030 (Units, Thousand)
Figure 19.231 Autoinjectors Market for Asthma in North America: Distribution by Type of Molecule, 2021-2030 (Units, Thousand)
Figure 19.232 Autoinjectors Market for Asthma in Europe, 2021-2030 (Units, Thousand)
Figure 19.233 Autoinjectors Market for Asthma in Europe: Distribution by Usability, 2021-2030 (Units, Thousand)
Figure 19.234 Autoinjectors Market for Asthma in Europe: Distribution by Route of Administration, 2021-2030 (Units, Thousand)
Figure 19.235 Autoinjectors Market for Asthma in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Thousand)
Figure 19.236 Autoinjectors Market for Asthma in Asia Pacific, 2021-2030 (Units, Thousand)
Figure 19.237 Autoinjectors Market for Asthma in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Thousand)
Figure 19.238 Autoinjectors Market for Asthma in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Thousand)
Figure 19.239 Autoinjectors Market for Asthma in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Thousand)
Figure 19.240 Autoinjectors Market for Asthma in Rest of the World, 2021-2030 (Units, Thousand)
Figure 19.241 Autoinjectors Market for Asthma in Rest of the World: Distribution by Usability, 2021-2030 (Units, Thousand)
Figure 19.242 Autoinjectors Market for Asthma in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Thousand)
Figure 19.243 Autoinjectors Market for Asthma in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Thousand)
Figure 19.244 Global Autoinjectors Market for Other Indications, 2021-2030 (USD Million)
Figure 19.245 Autoinjectors Market for Other Indications in North America, 2021-2030 (USD Million)
Figure 19.246 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.247 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.248 Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.249 Autoinjectors Market for Other Indications in Europe, 2021-2030 (USD Million)
Figure 19.250 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.251 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.252 Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.253 Autoinjectors Market for Other Indications in Asia Pacific, 2021-2030 (USD Million)
Figure 19.254 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.255 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.256 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.257 Autoinjectors Market for Other Indications in Rest of the World, 2021-2030 (USD Million)
Figure 19.258 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Figure 19.259 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Figure 19.260 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Figure 19.261 Global Autoinjectors Market for Other Indications, 2021-2030 (Units, Million)
Figure 19.262 Autoinjectors Market for Other Indications in North America, 2021-2030 (Units, Million)
Figure 19.263 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.264 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.265 Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.266 Autoinjectors Market for Other Indications in Europe, 2021-2030 (Units, Million)
Figure 19.267 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.268 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.269 Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.270 Autoinjectors Market for Other Indications in Asia Pacific, 2021-2030 (Units, Million)
Figure 19.271 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.272 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.273 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Figure 19.274 Autoinjectors Market for Other Indications in Rest of the World, 2021-2030 (Units, Million)
Figure 19.275 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Figure 19.276 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Figure 19.277 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)

List Of Tables

Table 3.1 Comparison of Self-Injection Devices
Table 3.2 Benefits of Autoinjectors
Table 4.1 Cartridge Manufacturers
Table 4.2 Glass Prefilled Syringes Available in the Market
Table 4.3 Plastic Prefilled Syringes Available in the Market
Table 4.4 Vials Available in the Market
Table 4.5 Comparison of Fabrication Material Used for Primary Drug Containers
Table 5.1 Autoinjectors: List of Devices
Table 5.2 Autoinjectors: List of Developers
Table 8.1 Patent Analysis: Prominent CPC Symbols
Table 8.2 Patent Analysis: Most Popular CPC Symbols
Table 8.3 Patent Analysis: List of Top CPC Symbols
Table 8.4 Patent Analysis: Summary of Benchmarking Analysis
Table 8.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 8.6 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 9.1 Autoinjector Combination Products: List of Approved Drugs
Table 9.2 Autoinjector Combination Products: List of Pipeline Drugs
Table 9.3 Autoinjector Combination Products: List of Developers
Table 10.1 Autoinjector-based Combination Products Available / Under Evaluation
Table 10.2 Adrenaline: Commercially Available Autoinjectors
Table 10.3 Adrenaline: Other Formulations
Table 10.4 Interferon β-1a Autoinjectors
Table 10.5 Interferon β-1b Autoinjectors
Table 10.6 Interferon-β Drugs: Other Dosage Forms
Table 10.7 Migraine: Commercially Available Autoinjectors
Table 10.8 Sumatriptan Succinate: Other Formulations
Table 10.9 Rheumatoid Arthritis: Commercially Available Autoinjectors
Table 11.1 Marketed Molecules: Most Likely Drug Candidates
Table 11.2 Marketed Molecules: Likely Drug Candidates
Table 11.3 Marketed Molecules: Less Likely Drug Candidates
Table 11.4 Marketed Molecules: Unlikely Drug Candidates
Table 11.5 Pipeline Molecules: Most Likely Drug Candidates
Table 11.6 Pipeline Molecules: Likely Drug Candidates
Table 11.7 Pipeline Molecules: Less Likely Drug Candidates
Table 11.8 Pipeline Molecules: Unlikely Drug Candidates
Table 12.1 Companies Profiled
Table 12.2 Antares Pharma: Company Snapshot
Table 12.3 Antares Pharma: Recent Developments and Future Outlook
Table 12.4 Bespak: Company Snapshot
Table 12.5 Bespak: Recent Developments and Future Outlook
Table 12.6 Dali Medical Devices: Company Snapshot
Table 12.7 DALI Medical Devices: Recent Developments and Future Outlook
Table 12.8 Elcam Medical: Company Snapshot
Table 12.9 Elcam Medical: Comparison of Autoinjectors
Table 12.10 Jiangsu Delfu Medical Devices: Company Snapshot
Table 12.11 Jiangsu Delfu: Autoinjectors
Table 12.12 Delfu Autoinjectors: Specifications
Table 12.13 Oval Medical Technologies: Company Snapshot
Table 12.14 Oval Medical: Recent Developments and Future Outlook
Table 12.15 Owen Mumford: Company Snapshot
Table 12.16 Owen Mumford: Comparison of Autoinjectors
Table 12.17 Owen Mumford: Recent Developments and Future Outlook
Table 12.18 SHL Group: Company Snapshot
Table 12.19 SHL: Comparison of Two-Step Disposable Autoinjectors
Table 12.20 SHL: Comparison of Three-Step Disposable Autoinjectors
Table 12.21 SHL Group: Recent Developments and Future Outlook
Table 12.22 Union Medico: Company Snapshot
Table 12.23 Union Medico: Comparison of 45? Autoinjectors
Table 12.24 Union Medico: Comparison of 90? Autoinjectors
Table 12.25 Ypsomed: Company Snapshot
Table 12.26 YpsoMate Autoinjectors: Dimensions of Prefilled Syringes
Table 12.27 Ypsomed: Comparison of Autoinjectors
Table 12.28 Ypsomed: Recent Developments and Future Outlook
Table 13.1 AktiVax: Company Details
Table 13.2 Amneal Pharmaceuticals: Company Details
Table 13.3 kaléo: Company Details
Table 13.4 MiniEpi: Company Details
Table 13.5 Nemera: Company Details
Table 13.6 Nuance Designs: Company Details
Table 13.7 Windgap Medical: Company Details
Table 13.8 Xeris Pharmaceuticals: Company Details
Table 13.9 Zion Clinical Pharmacy: Company Details
Table 14.1 KOL Analysis: List of Principal Investigators / Sub-Investigators / Study Directors
Table 14.2 KOL Analysis: Number of Publications and Citations
Table 14.3 KOL Analysis: List of Patents Applicants
Table 14.4 KOL Analysis: Number of Affiliations, LinkedIn Connections and Years of Experience
Table 15.1 Antibody Drug Conjugates: List of Partnerships and Collaborations, 2014-2021
Table 17.1 List of Medical Device CMOs Offering Services for Drug Delivery Devices
Table 17.2 Medical Device CMOs Offering Services for Drug Delivery Devices: Information on Production Services
Table 18.1 Prefilled Syringes: List of Available / Under Development Devices
Table 18.2 Prefilled Syringes: List of Developers
Table 20.1 DALI Medical Devices: Company Snapshot
Table 20.2 Oval Medical Technologies: Company Snapshot
Table 20.3 Duoject Medical Systems: Company Snapshot
Table 20.4 PHC: Company Snapshot
Table 20.5 Elcam Medical: Company Snapshot
Table 20.6 IDEO: Company Snapshot
Table 20.7 Bill & Melinda Gates Foundation: Company Snapshot
Table 22.1 Autoinjectors: Distribution by Usability
Table 22.2 Autoinjectors: Distribution by Type of Primary Container
Table 22.3 Autoinjectors: Distribution by Type of Dose
Table 22.4 Autoinjectors: Distribution by Route of Administration
Table 22.5 Autoinjectors: Distribution by Actuation Mechanism
Table 22.6 Autoinjectors: Distribution by Type of Feedback Mechanism
Table 22.7 Autoinjector Device Developers: Distribution by Year of Establishment
Table 22.8 Autoinjector Device Developers: Distribution by Company Size
Table 22.9 Patent Analysis: Distribution by Type of Patent
Table 22.10 Patent Analysis: Cumulative Distribution by Application Year
Table 22.11 Patent Analysis: Year-wise Distribution by Application Year
Table 22.12 Patent Analysis: Distribution by Issuing Authority
Table 22.13 Patent Analysis: Distribution by Leading Assignees
Table 22.14 Patent Analysis: Distribution by Patent Age
Table 22.15 Approved Autoinjector Combination Products: Cumulative Number of Approvals by Initial Year of Approval
Table 22.16 Approved Autoinjector Combination Products: Distribution by Usability
Table 22.17 Approved Autoinjector Combination Products: Distribution by Route of Administration
Table 22.18 Approved Autoinjector Combination Products: Distribution by Primary Drug Container
Table 22.19 Approved Autoinjector Combination Products: Distribution by Type of Molecule
Table 22.20 Approved Autoinjector Combination Products: Distribution by Dose Strength
Table 22.21 Approved Autoinjector Combination Products: Distribution by Therapeutic Indication
Table 22.22 Approved Autoinjector Combination Products: Distribution by Other Packaging Formats of Marketed Drugs
Table 22.23 Pipeline Autoinjector Combination Products: Distribution by Phase of Development
Table 22.24 Pipeline Autoinjector Combination Products: Distribution by Route of Administration
Table 22.25 Pipeline Autoinjector Combination Products: Distribution by Type of Molecule
Table 22.26 Autoinjector Combination Product Developers: Distribution by Year of Establishment
Table 22.27 Autoinjector Combination Product Developers: Distribution by Company Size
Table 22.28 EpiPen: Historical Drug Sales (USD Billion), 2012-2017
Table 22.29 Interferon β-1a: Historical Sales (USD Billion), 2014-2020
Table 22.30 Interferon β-1b: Historical Sales (USD Million), 2014-2020
Table 22.31 Migraine: Historical Drug Sales (USD Million), 2014-2020
Table 22.32 Rheumatoid Arthritis: Historical Drug Sales (USD Billion), 2014-2020
Table 22.33 Antares Pharma: Annual Revenues, 2014- H1 2021 (USD Million)
Table 22.34 Consort Medical: Annual Revenues, 2014-2019 (GBP Million)
Table 22.35 Ypsomed: Annual Revenues, 2014-15 - 2020-21 (CHF Million)
Table 22.36 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Table 22.37 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2014-2021
Table 22.38 Partnerships and Collaborations: Distribution by Type of Partnership
Table 22.39 Partnerships and Collaborations: Cumulative Trend by Year and Type of Partnership, 2014-2021
Table 22.40 Most Active Players: Distribution by Number of Partnerships
Table 22.41 Partnerships and Collaborations: Regional Distribution
Table 22.42 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Table 22.43 Prefilled Syringes: Distribution by Number of Barrel Chambers
Table 22.44 Prefilled Syringes: Distribution by Type of Needle System
Table 22.45 Prefilled Syringes: Distribution by Device Capacity
Table 22.46 Prefilled Syringe Developers: Distribution by Year of Establishment
Table 22.47 Prefilled Syringe Developers: Distribution by Company Size
Table 22.48 Prefilled Syringe Developers: Distribution by Geographical Location of Headquarters
Table 22.49 Prefilled Syringe Developers: Distribution by Geographical Location of Manufacturing Facilities
Table 22.50 Technological Evolution of Prefilled Syringes
Table 22.51 Drug Delivery Device Service Provider: Distribution by Year of Establishment
Table 22.52 Global Autoinjectors Market, 2021-2030 (USD Million)
Table 22.53 Global Autoinjectors Market: Distribution by Usability, 2021-2030 (USD Million)
Table 22.54 Global Autoinjectors Market: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.55 Global Autoinjectors Market: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.56 Autoinjectors Market in North America, 2021-2030 (USD Million)
Table 22.58 Autoinjectors Market in North America: Distribution by Usability, 2021-2030 (USD Million)
Table 22.59 Autoinjectors Market in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.60 Autoinjectors Market in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.61 Autoinjectors Market in Europe, 2021-2030 (USD Million)
Table 22.62 Autoinjectors Market in Europe: Distribution by Usability, 2021-2030 (USD Million)
Table 22.63 Autoinjectors Market in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.64 Autoinjectors Market in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.65 Autoinjectors Market in Asia Pacific, 2021-2030 (USD Million)
Table 22.66 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Table 22.67 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.68 Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.69 Autoinjectors Market in Rest of the World, 2021-2030 (USD Million)
Table 22.70 Autoinjectors Market in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Table 22.71 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.72 Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.73 Global Autoinjectors Market, 2021-2030 (Units, Million)
Table 22.74 Global Autoinjectors Market: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.75 Global Autoinjectors Market: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.76 Global Autoinjectors Market: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.77 Autoinjectors Market in North America, 2021-2030 (Units, Million)
Table 22.78 Autoinjectors Market in North America: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.79 Autoinjectors Market in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.80 Autoinjectors Market in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.81 Autoinjectors Market in Europe, 2021-2030 (Units, Million)
Table 22.82 Autoinjectors Market in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.83 Autoinjectors Market in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.84 Autoinjectors Market in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.85 Autoinjectors Market in Asia Pacific, 2021-2030 (Units, Million)
Table 22.86 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.87 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.88 Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.89 Autoinjectors Market in Rest of the World, 2021-2030 (Units, Million)
Table 22.90 Autoinjectors Market in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.91 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.91 Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.93 Global Autoinjectors Market for Anaphylaxis, 2021-2030 (USD Million)
Table 22.94 Autoinjectors Market for Anaphylaxis in North America, 2021-2030 (USD Million)
Table 22.95 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2021-2030 (USD Million)
Table 22.96 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.97 Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.98 Autoinjectors Market for Anaphylaxis in Europe, 2021-2030 (USD Million)
Table 22.99 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2021-2030 (USD Million)
Table 22.100 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.101 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.102 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2021-2030 (USD Million)
Table 22.103 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Table 22.104 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.105 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.106 Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2030 (USD Million)
Table 22.107 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Table 22.108 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.109 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.110 Global Autoinjectors Market for Anaphylaxis, 2021-2030 (Units, Million)
Table 22.111 Autoinjectors Market for Anaphylaxis in North America, 2021-2030 (Units, Million)
Table 22.112 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.113 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.114 Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.115 Autoinjectors Market for Anaphylaxis in Europe, 2021-2030 (Units, Million)
Table 22.116 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.117 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.118 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.119 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2021-2030 (Units, Million)
Table 22.120 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.121 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.122 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.123 Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2030 (Units, Million)
Table 22.124 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.125 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.126 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.127 Global Autoinjectors Market for Multiple Sclerosis, 2021-2030 (USD Million)
Table 22.128 Autoinjectors Market for Multiple Sclerosis in North America, 2021-2030 (USD Million)
Table 22.129 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2021-2030 (USD Million)
Table 22.130 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.131 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.132 Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2030 (USD Million)
Table 22.133 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2021-2030 (USD Million)
Table 22.134 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.135 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.136 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2021-2030 (USD Million)
Table 22.137 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Table 22.138 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.139 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.140 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2030 (USD Million)
Table 22.141 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Table 22.142 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.143 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.144 Global Autoinjectors Market for Multiple Sclerosis, 2021-2030 (Units, Million)
Table 22.145 Autoinjectors Market for Multiple Sclerosis in North America, 2021-2030 (Units, Million)
Table 22.146 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.147 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.148 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.149 Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2030 (Units, Million)
Table 22.150 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.151 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.152 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.153 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2021-2030 (Units, Million)
Table 22.154 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.155 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.156 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.157 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2030 (Units, Million)
Table 22.158 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.159 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.160 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.161 Global Autoinjectors Market for Rheumatoid Arthritis, 2021-2030 (USD Million)
Table 22.162 Autoinjectors Market for Rheumatoid Arthritis in North America, 2021-2030 (USD Million)
Table 22.163 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2021-2030 (USD Million)
Table 22.164 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.165 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.166 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2021-2030 (USD Million)
Table 22.167 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2021-2030 (USD Million)
Table 22.168 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.169 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.170 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2021-2030 (USD Million)
Table 22.171 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Table 22.172 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.173 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.174 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2021-2030 (USD Million)
Table 22.175 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Table 22.176 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.177 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.178 Global Autoinjectors Market for Rheumatoid Arthritis, 2021-2030 (Units, Million)
Table 22.179 Autoinjectors Market for Rheumatoid Arthritis in North America, 2021-2030 (Units, Million)
Table 22.180 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.181 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.182 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.183 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2021-2030 (Units, Million)
Table 22.184 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.185 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.186 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.187 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2021-2030 (Units, Million)
Table 22.188 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.189 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.190 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.191 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2021-2030 (Units, Million)
Table 22.192 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.193 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.194 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.195 Global Autoinjectors Market for Migraine, 2021-2030 (USD Million)
Table 22.196 Autoinjectors Market for Migraine in North America, 2020-2030 (USD Million)
Table 22.197 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2021-2030 (USD Million)
Table 22.198 Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.199 Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.200 Autoinjectors Market for Migraine in Europe, 2021-2030 (USD Million)
Table 22.201 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2021-2030 (USD Million)
Table 22.202 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.203 Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.204 Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (USD Million)
Table 22.205 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Table 22.206 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.207 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.208 Autoinjectors Market for Migraine in Rest of the World, 2021-2030 (USD Million)
Table 22.209 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Table 22.210 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.211 Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.212 Global Autoinjectors Market for Migraine, 2021-2030 (Units, Million)
Table 22.213 Autoinjectors Market for Migraine in North America, 2021-2030 (Units, Million)
Table 22.214 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.215 Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.216 Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.217 Autoinjectors Market for Migraine in Europe, 2021-2030 (Units, Million)
Table 22.218 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.219 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.220 Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.221 Autoinjectors Market for Migraine in Asia Pacific, 2021-2030 (Units, Million)
Table 22.222 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.223 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.224 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.225 Autoinjectors Market for Migraine in Rest of the World, 2021-2030 (Units, Million)
Table 22.226 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.227 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.228 Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.229 Global Autoinjectors Market for Diabetes, 2021-2030 (USD Million)
Table 22.230 Autoinjectors Market for Diabetes in North America, 2021-2030 (USD Million)
Table 22.231 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2021-2030 (USD Million)
Table 22.232 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.233 Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.234 Autoinjectors Market for Diabetes in Europe, 2021-2030 (USD Million)
Table 22.235 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2021-2030 (USD Million)
Table 22.236 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.237 Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.238 Autoinjectors Market for Diabetes in Asia Pacific, 2021-2030 (USD Million)
Table 22.239 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Table 22.240 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.241 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.242 Autoinjectors Market for Diabetes in Rest of the World, 2021-2030 (USD Million)
Table 22.243 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Table 22.244 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.245 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.246 Global Autoinjectors Market for Diabetes, 2021-2030 (Units, Million)
Table 22.247 Autoinjectors Market for Diabetes in North America, 2021-2030 (Units, Million)
Table 22.248 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.249 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.250 Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.251 Autoinjectors Market for Diabetes in Europe, 2021-2030 (Units, Million)
Table 22.252 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.253 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.254 Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.255 Autoinjectors Market for Diabetes in Asia Pacific, 2021-2030 (Units, Million)
Table 22.256 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.257 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.258 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.259 Autoinjectors Market for Diabetes in Rest of the World, 2021-2030 (Units, Million)
Table 22.260 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.261 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.262 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.263 Global Autoinjectors Market for Asthma, 2021-2030 (USD Thousands)
Table 22.264 Autoinjectors Market for Asthma in North America, 2021-2030 (USD Thousands)
Table 22.265 Autoinjectors Market for Asthma in North America: Distribution by Usability, 2021-2030 (USD Thousands)
Table 22.266 Autoinjectors Market for Asthma in North America: Distribution by Route of Administration, 2021-2030 (USD Thousands)
Table 22.267 Autoinjectors Market for Asthma in North America: Distribution by Type of Molecule, 2021-2030 (USD Thousands)
Table 22.268 Autoinjectors Market for Asthma in Europe, 2021-2030 (USD Thousands)
Table 22.269 Autoinjectors Market for Asthma in Europe: Distribution by Usability, 2021-2030 (USD Thousands)
Table 22.270 Autoinjectors Market for Asthma in Europe: Distribution by Route of Administration, 2021-2030 (USD Thousands)
Table 20.271 Autoinjectors Market for Asthma in Europe: Distribution by Type of Molecule, 2021-2030 (USD Thousands)
Table 22.272 Autoinjectors Market for Asthma in Asia Pacific, 2021-2030 (USD Thousands)
Table 22.273 Autoinjectors Market for Asthma in Asia Pacific: Distribution by Usability, 2021-2030 (USD Thousands)
Table 22.274 Autoinjectors Market for Asthma in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Thousands)
Table 22.275 Autoinjectors Market for Asthma in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Thousands)
Table 22.276 Autoinjectors Market for Asthma in Rest of the World, 2021-2030 (USD Thousands)
Table 22.277 Autoinjectors Market for Asthma in Rest of the World: Distribution by Usability, 2021-2030 (USD Thousands)
Table 22.278 Autoinjectors Market for Asthma in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Thousands)
Table 22.279 Autoinjectors Market for Asthma in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Thousands)
Table 22.280 Global Autoinjectors Market for Asthma, 2021-2030 (Units, Thousands)
Table 22.281 Autoinjectors Market for Asthma in North America, 2021-2030 (Units, Thousands)
Table 22.282 Autoinjectors Market for Asthma in North America: Distribution by Usability, 2021-2030 (Units, Thousands)
Table 22.283 Autoinjectors Market for Asthma in North America: Distribution by Route of Administration, 2021-2030 (Units, Thousands)
Table 22.284 Autoinjectors Market for Asthma in North America: Distribution by Type of Molecule, 2021-2030 (Units, Thousands)
Table 22.285 Autoinjectors Market for Asthma in Europe, 2021-2030 (Units, Thousands)
Table 22.286 Autoinjectors Market for Asthma in Europe: Distribution by Usability, 2021-2030 (Units, Thousands)
Table 22.287 Autoinjectors Market for Asthma in Europe: Distribution by Route of Administration, 2021-2030 (Units, Thousands)
Table 22.288 Autoinjectors Market for Asthma in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Thousands)
Table 22.289 Autoinjectors Market for Asthma in Asia Pacific, 2021-2030 (Units, Thousands)
Table 22.290 Autoinjectors Market for Asthma in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Thousands)
Table 22.291 Autoinjectors Market for Asthma in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Thousands)
Table 22.292 Autoinjectors Market for Asthma in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Thousands)
Table 22.293 Autoinjectors Market for Asthma in Rest of the World, 2021-2030 (Units, Thousands)
Table 22.294 Autoinjectors Market for Asthma in Rest of the World: Distribution by Usability, 2021-2030 (Units, Thousands)
Table 22.295 Autoinjectors Market for Asthma in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Thousands)
Table 22.296 Autoinjectors Market for Asthma in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Thousands)
Table 22.297 Global Autoinjectors Market for Other Indications, 2021-2030 (USD Million)
Table 22.298 Autoinjectors Market for Other Indications in North America, 2021-2030 (USD Million)
Table 22.299 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2021-2030 (USD Million)
Table 22.300 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.301 Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.302 Autoinjectors Market for Other Indications in Europe, 2021-2030 (USD Million)
Table 22.303 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2021-2030 (USD Million)
Table 22.304 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.305 Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.306 Autoinjectors Market for Other Indications in Asia Pacific, 2021-2030 (USD Million)
Table 22.307 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2021-2030 (USD Million)
Table 22.308 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.309 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.310 Autoinjectors Market for Other Indications in Rest of the World, 2021-2030 (USD Million)
Table 22.311 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2021-2030 (USD Million)
Table 22.312 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2021-2030 (USD Million)
Table 22.313 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2021-2030 (USD Million)
Table 22.314 Global Autoinjectors Market for Other Indications, 2021-2030 (Units, Million)
Table 22.315 Autoinjectors Market for Other Indications in North America, 2021-2030 (Units, Million)
Table 22.316 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.317 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.318 Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.319 Autoinjectors Market for Other Indications in Europe, 2021-2030 (Units, Million)
Table 22.320 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.321 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.322 Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.323 Autoinjectors Market for Other Indications in Asia Pacific, 2021-2030 (Units, Million)
Table 22.324 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.325 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.326 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.327 Autoinjectors Market for Other Indications in Rest of the World, 2021-2030 (Units, Million)
Table 22.328 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2021-2030 (Units, Million)
Table 22.329 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2021-2030 (Units, Million)
Table 22.330 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2021-2030 (Units, Million)
Table 22.331 Global Autoinjectors Market: Conservative, Base and Optimistic Forecast Scenarios, 2021 and 2030 (USD Million)
Table 22.332 Global Autoinjectors Market: Conservative, Base and Optimistic Forecast Scenarios, 2021 and 2030 (Units, Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. AbbVie 
  2. Aktiv Pharma Group
  3. ALK-Abelló 
  4. Allergy Therapeutics
  5. Alvogen
  6. Alvotech
  7. AMAG Pharmaceuticals
  8. Amgen
  9. Amneal Pharmaceuticals
  10. Amphastar Pharmaceuticals
  11. Androsystems
  12. Antares Pharma
  13. Aptar
  14. Asahi Kasei Pharma
  15. Ascendis Pharma
  16. AstraZeneca
  17. Battelle
  18. Bayer
  19. Becton Dickinson
  20. Bespak (acquired by Recipharm)
  21. Biocorp
  22. Biogen
  23. BioGene Pharmaceutical
  24. Boehringer Ingelheim
  25. Bristol-Myers Squibb
  26. Cambridge Consultants
  27. Celltrion
  28. ChemProtect.SK
  29. Chugai Pharmaceutical
  30. CinnaGen
  31. Creare
  32. Crossject
  33. DALI Medical Devices
  34. Dr. Reddy's Laboratories
  35. Duoject Medical Systems
  36. Elcam Medical
  37. Eli Lilly
  38. EMD Serono
  39. Eton Pharmaceuticals
  40. F. Hoffmann-La Roche 
  41. Ferring Pharmaceuticals
  42. Fresenius Kabi
  43. Fujifilm Kyowa Kirin Biologics
  44. Genentech (subsidiary of Roche)
  45. GlaxoSmithKline
  46. Grand Pharma
  47. Idorsia Pharmaceuticals
  48. Impax Pharmaceuticals (subsidiary of Amneal Pharmaceuticals)
  49. Jabil
  50. Janssen Biotech
  51. Janssen Research and Development
  52. JCR Pharmaceuticals 
  53. Jiangsu Delfu medical device
  54. Kaléo
  55. King Pharmaceuticals (acquired by Pfizer)
  56. LG Chem
  57. Lincoln Medical (acquired by Bioprojet Pharma)
  58. Lineage Cell Therapeutics
  59. Lunatus Medical Company
  60. Medexus Pharmaceuticals
  61. Medicom Innovation Partner (acquired by Phillips-Medisize)
  62. Merck
  63. Meridian Medical Technologies
  64. Midas Pharma
  65. MiniEpi
  66. Momenta Pharmaceuticals
  67. Mylan
  68. Nemera
  69. Neuma
  70. Nipro
  71. Novartis
  72. Ology Bioservices (subsidiary of National Resilience)
  73. Oval Medical Technologies (acquired by SMC)
  74. Owen Mumford
  75. PA Consulting Group
  76. Palatin Technologies
  77. Pfizer
  78. PharmaConsult
  79. Phillips-Medisize (acquired by Molex)
  80. Promius Pharma (subsidiary of Dr. Reddy's Laboratories)
  81. Rafa Laboratories
  82. RAVIMED
  83. Regeneron Pharmaceuticals
  84. Rx Bandz
  85. Samsung Bioepis
  86. Sandoz
  87. Sanofi
  88. Shire (subsidiary of Takeda Pharmaceutical)
  89. SHL Medical
  90. Stevanato Group
  91. Sumitomo Dainippon Pharma
  92. Sun Pharmaceutical Industries
  93. Survival Technologies
  94. Symatese
  95. Takeda Pharmaceutical Company
  96. Teva Pharmaceutical Industries
  97. UCB Biopharma
  98. Union Medico
  99. US WorldMeds
  100. Bausch Health Companies (formerly Valeant Pharmaceuticals International)
  101. Weibel CDS (subsidiary of SHL Medical)
  102. Weiss-Aug
  103. West Pharmaceutical Services
  104. Windgap Medical
  105. Xeris Pharmaceuticals
  106. Ypsomed
  107. Zion Clinical Pharmacy 

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com